RCAMU
MYGN icon

Rothschild & Co Asset Management US’s Myriad Genetics MYGN Stock Holding History

Rothschild & Co Asset Management US’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-889,892
Closed -$24.2M – 352
2019
Q4 		$24.2M Sell
889,892
-56,026
-6% -$1.54M 0.25% 172
2019
Q3 		$27.1M Sell
945,918
-6,900
-0.7% -$201K 0.29% 149
2019
Q2 		$26.5M Buy
952,818
+127,158
+15% +$3.59M 0.28% 149
2019
Q1 		$27.4M Buy
+825,660
New +$25.1M 0.29% 128

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rothschild & Co Asset Management US's MYGN Position: Q1 2020 in Review

Rothschild & Co Asset Management US sold out of Myriad Genetics (MYGN) in Q1 2020, closing a stake of 889,892 shares — an estimated $24.2M sold.

Rothschild & Co Asset Management US first reported a position in MYGN in Q1 2019 and held it in 4 quarters. The position peaked at $27.4M in Q1 2019. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

  • Rothschild & Co Asset Management US reported no remaining Myriad Genetics position as of Q1 2020 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 889,892 Myriad Genetics shares in Q1 2020, an estimated $24.2M.
  • Rothschild & Co Asset Management US first reported a position in Myriad Genetics in Q1 2019 and held it in 4 quarters.
  • Rothschild & Co Asset Management US's Myriad Genetics position peaked at $27.4M in Q1 2019.
  • 190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on Rothschild & Co Asset Management US's 13F filing for Q1 2020, filed 14 May 2020.